Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on Crinetics (CRNX) to $108 from $143 and keeps an Outperform rating on the shares. Crinetics has hit the ground running following Palsonify’s approval in late September, with the first revenue coming in January, which will help set expectations for the launch curve, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharmaceuticals Reports Positive Launch and Financials
- Crinetics reports Q3 EPS ($1.38), consensus ($1.25)
- Crinetics Pharmaceuticals: Promising PFS Data and Strategic Focus Justify Buy Rating
- Crinetics Pharma’s Atumelnant Study: A Promising Phase 1 Update
- Crinetics Pharma’s Paltusotine Study: A Potential Game-Changer for Carcinoid Syndrome